Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group

References

• Geisler CH, Kolstad A, Laurell A, . Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, . Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose Ara-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma; results of the MCL younger trial of the European Mantle Cell Lymphoma Network. Blood 2010;116(Suppl. 1): Abstract 110.
   Google Scholar
• Zucca E, Roggero E, Pinotti G, . Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257–262.
   PubMed Web of Science ®Google Scholar
• Samaha H, Dumontet C, Ketterer N, . Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998;12:1281–1287.
   PubMed Web of Science ®Google Scholar
• Oinonen R, Franssila K, Teerenhovi L, . Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998;34:329–336.
   PubMed Web of Science ®Google Scholar
• Räty R, Franssila K, Joensuu H, . Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002;69:11–20.
   PubMed Web of Science ®Google Scholar
• Herrmann A, Hoster E, Zwingers T, . Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511–518.
   PubMed Web of Science ®Google Scholar
• Abrahamsson A, Dahle N, Jerkeman M. Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma 2011;52: 1929–1935.
   PubMed Web of Science ®Google Scholar
• Griffiths R, Mikhael J, Gleeson M, . Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011;118: 4808–4816.
   PubMed Web of Science ®Google Scholar
• Foran JM, Cunningham D, Coiffier B, . Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000;11(Suppl. 1):117–121.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Burki K, . The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000;11(Suppl. 1): 123–126.
   PubMed Web of Science ®Google Scholar
• Howard OM, Gribben JG, Neuberg DS, . Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288–1294.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, . Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004;101:883–893.
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, . Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114: 800–809.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, . The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–3071.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Cortelazzo S, Magni M, . Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002;29(Suppl. 1):S10–S13.
   Google Scholar
• Geisler CH, Elonen E, Kolstad A, . Nordic Mantle Cell Lymphoma (MCL) Project: prolonged follow-up of 86 patients treated with BEAM/BEAC + PBSCT confirms that addition of high-dose Ara-C and rituximab to CHOP induction + in-vivo purging with rituximab increases clinical and molecular response rates, PCR-neg. grafts, failure-free, relapse-free and overall survival. Blood 2004; 104(Suppl. 1):8.
   Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, . Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003–4008.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, . Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Salles G, . Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011;103:1799–1806.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans J, Hoster E, Vehling-Kaiser U, . Rituximab maintenance significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. First results of a randomized trial of The European MCL Network. Haematologica 2011;96(Suppl.): Abstract 504.
   Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, . Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803–3809.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Khouri IF, Kantarjian HM, . Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000;39:77–85.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Suzan F, . Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587–593.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Estey E, Du M, . Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 1997;3:1539–1545.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, . A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans JC, Hoster E, Hermine O, . R-CHOP versus R-FC followed by maintenance with rituximab or IFN: first results of a randomized trial for elderly patients with mantle cell lymphoma. Ann Oncol 2011;22(Suppl.): Abstract 16.
   Google Scholar
• Ruan J, Martin P, Furman RR, . Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, . High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, Feng L, . Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010;150:200–208.
   PubMed Web of Science ®Google Scholar
• Carney DA, Westerman DA, Tam CS, . Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010;24:2056–2062.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Rufibach K, Salles G, . Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675–1682.
   PubMed Web of Science ®Google Scholar
• Andersen NS, Pedersen LB, Laurell A, . Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27: 4365–4370.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 2006;30(Suppl. 1):S16–S21.
   PubMed Web of Science ®Google Scholar
• Aksoy S, Harputluoglu H, Kilickap S, . Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307–1312.
   PubMed Web of Science ®Google Scholar
• Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308–318.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Spedini P, Casari S, . Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47: 1013–1017.
   PubMed Web of Science ®Google Scholar
• Liu JH, Wei S, Lamy T, . Chronic neutropenia mediated by fas ligand. Blood 2000;95:3219–3222.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Papadaki T, Pontikoglou C, . Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia 2008;22:1446–1449.
   PubMed Web of Science ®Google Scholar
• Grant C, Wilson WH, Dunleavy K. >Neutropenia associated with rituximab therapy. Curr Opin Hematol 2010 Nov 22. [Epub ahead of print]
   Web of Science ®Google Scholar
• Keane C, Nourse JP, Crooks P. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J 2011 Sep 1. [Epub ahead of print]
   Web of Science ®Google Scholar
• Hincks I, Woodcock BE, Thachil J. Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br J Haematol 2011;153:411–413.
   PubMed Web of Science ®Google Scholar
• Pott C, Schrader C, Gesk S, . Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006;107:2271–2278.
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, . Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL Intergroup study. Blood 2010;115:3215–3223.
   PubMed Web of Science ®Google Scholar
• Böttcher S, Ritgen M, Buske S, . Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-colour flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008;93:551–559.
   PubMed Web of Science ®Google Scholar
• Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol 2011;80:69–86.
   PubMed Web of Science ®Google Scholar